Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Insider Sells $12,836.22 in Stock

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) insider Gina Mazzariello sold 3,678 shares of the firm’s stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $3.49, for a total transaction of $12,836.22. Following the transaction, the insider now directly owns 139,090 shares of the company’s stock, valued at approximately $485,424.10. This trade represents a 2.58 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Amylyx Pharmaceuticals Stock Performance

Shares of NASDAQ:AMLX traded up $0.07 during mid-day trading on Wednesday, hitting $3.69. 1,581,960 shares of the company traded hands, compared to its average volume of 986,350. The firm has a market cap of $252.95 million, a P/E ratio of -0.97 and a beta of -0.54. Amylyx Pharmaceuticals, Inc. has a 52-week low of $1.58 and a 52-week high of $19.95. The firm’s 50 day simple moving average is $4.07 and its 200 day simple moving average is $3.66.

Wall Street Analysts Forecast Growth

AMLX has been the topic of a number of analyst reports. Robert W. Baird upgraded shares of Amylyx Pharmaceuticals from a “neutral” rating to an “outperform” rating and raised their target price for the stock from $3.00 to $11.00 in a research report on Monday, November 18th. Bank of America upgraded shares of Amylyx Pharmaceuticals from a “neutral” rating to a “buy” rating and raised their target price for the stock from $4.20 to $10.00 in a research report on Wednesday, October 23rd. HC Wainwright restated a “buy” rating and set a $12.00 target price on shares of Amylyx Pharmaceuticals in a research report on Thursday, December 5th. Leerink Partners set a $4.00 target price on shares of Amylyx Pharmaceuticals and gave the stock a “market perform” rating in a research report on Friday, October 18th. Finally, Baird R W upgraded shares of Amylyx Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Monday, November 18th. Five equities research analysts have rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $7.33.

Institutional Investors Weigh In On Amylyx Pharmaceuticals

Several hedge funds have recently modified their holdings of the stock. Blue Trust Inc. raised its holdings in shares of Amylyx Pharmaceuticals by 232.1% during the 4th quarter. Blue Trust Inc. now owns 6,987 shares of the company’s stock valued at $26,000 after buying an additional 4,883 shares during the period. China Universal Asset Management Co. Ltd. raised its holdings in shares of Amylyx Pharmaceuticals by 63.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,094 shares of the company’s stock valued at $42,000 after buying an additional 5,104 shares during the period. Y Intercept Hong Kong Ltd purchased a new stake in shares of Amylyx Pharmaceuticals during the 4th quarter valued at about $56,000. Algert Global LLC purchased a new stake in shares of Amylyx Pharmaceuticals during the 2nd quarter valued at about $47,000. Finally, Barclays PLC raised its holdings in shares of Amylyx Pharmaceuticals by 91.1% during the 3rd quarter. Barclays PLC now owns 84,572 shares of the company’s stock valued at $274,000 after buying an additional 40,319 shares during the period. 95.84% of the stock is currently owned by hedge funds and other institutional investors.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.